series-b
Stage
About
Immunitas TX develops novel immunotherapies targeting CD161 for the treatment of cancer and autoimmune diseases, with programs in clinical and preclinical stages.
Explore Immunitas TX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.